Tau and α-synuclein autoantibodies as potential biomarkers for Parkinson’s and Alzheimer’s diseases
Objective: To investigate the value of the naturally occurring serum AIAs of α-synuclein (α-syn) and tau, proteins as potential biomarker for diagnosis of PD in…Broad White Matter Impairment in Multiple System Atrophy: A case for Oligodendrocyte Dysfunction
Objective: The main objective of this study was to investigate if there are widespread white matter abnormalities in multiple system atrophy (MSA). Background: MSA differs…Serum cholesterol level is associated with risk of MSA
Objective: We aim to ascertain the association between serum cholesterol and multiple system atrophy (MSA). Background: MSA, a common form of atypical parkinsonism, is a…Natural history of RBD in Parkinson´s disease and response to dopaminergic and non-dopaminergic antiparkinsonian treatment
Objective: To assess the natural history of rapid eye movement sleep behavior disorder (RBD) in patients with Parkinson´s disease (PD) and clarify its response to…PrP as a receptor of alpha-synuclein in the pancreas of patients with synucleinopathies
Objective: We have investigated whether the cellular prion protein interacts with alpha-synuclein in pancreatic cells of patients with synucleinopathies. Background: Neurodegenerative diseases such as Alzheimer’s…Delivery of AAV alpha synuclein to a mouse and rat provides a useful model for the assessment of anti-parkinsonian efficacy of chronic inhibition of LRRK2
Objective: 1. To create an in vivo model system to be used to assess the effect of chronically inhibiting LRRK2 pharmacologically. 2. To confirm previous…Rapamycin for treating MSA: A preclinical proof of concept study
Objective: To assess the effects of rapamycin on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synuclenopathies
Objective: We have investigated whether deposits of phosphorylated α-synuclein might be present in pancreatic tissue of subjects with synucleinopathies. Background: Parkinson’s disease patients experience a…Effects of Glial Heme Oxygenase-1 on Neuronal Alpha-Synuclein in the GFAP.HMOX1 Mouse Model of Parkinson’s Disease
Objective: To determine whether astroglial HO-1 transduces environmental and endogenous stressors into patterns of neural damage which promote the toxicity of neuronal alpha-synuclein. Background: The…The Small Molecule Alpha-Synuclein Misfolding Inhibitor, NPT200-11, Produces Multiple Benefits in an Animal Model of Parkinson’s Disease
Objective: To evaluate effects of NPT200-11 on Parkinson’s disease (PD)-relevant outcomes including alpha-synuclein pathology, neurodegenerative markers and motor performance in transgenic mouse models of PD.…
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 60
- Next Page »